CSI Market
Sign In | Register

Collplant Biotechnologies Ltd (CLGN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CLGN Annual Cash Flow →
From Collplant Biotechnologies Ltd through Dec 31 2024, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-11.49
Depreciation & amortization0.85
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.41
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.13
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation1.00
Income (Loss) from Equity Method Investments0.00
Adjustments ForFair Value Gains Losses0.00
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Sharebased Payments-
Adjustment For Exchange Differences On Cash And Cash Equivalents-
Adjustments For Increase Decrease In Trade Account Payable-
Adjustments For Increase Decrease In Other Operating Payables-
Adjustments For Increase Decrease In Contract Liabilities Including Longterm Contract Liabilities-
Adjustments For Increase Decrease In Royalties To Iia Including Short Term Royalties-
Net Cash Used In Operationssee Appendix A-
Effect Of Exchange Rate Changes On Cash And Cash Equivalent-
Financial Expenses Related To Financial Instruments-
Increase Decrease In Other Noncurrent Asset-
Accrued Interest-
Increase Decrease In Operating Lease Liability-
Income taxes6.07
Gain (Loss) on Sale of Investments0.00
Accounts Receivable-0.15
Increase (Decrease) in Accounts Payable, Trade-0.26
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.21
Other Working Capital-0.67
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.08
Discontinued operations0.00
Net Cash flow from Operating Activities-9.42
Investing Activities
Capital Expenditures0.03
Sale of Capital Items0.00
Short-term Investments Proceeds53.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceed From Other Short Term Deb-
Payments to Acquire Restricted Certificates of Deposit0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits6.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.03
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.50
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.10
Increase Decrease In Cash And Cash Equivalents-
Repayments Made For Equipment On Financing Terms-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Conversion Of Stock Amount Converted-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Proceeds From Issuance Of Shares And Warrants Less Issuance Expenses-
Proceeds From Exercise Of Options And Warrants Into Shares-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3.10
Effect of exchange rate on cash flow0.03
Discontinued operations0.00
Free Cash Flow-9.39
Total Cash Flow-6.32
4 historic quarters locked

Sign in to unlock the full Collplant Biotechnologies Ltd cash flow history.

Sign In Create Free Account

About Collplant Biotechnologies Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-034393

Figures are derived from filed reports and may be restated. Historical data is subject to revision.